Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05650580
Other study ID # TR115-CN-PI-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 23, 2023
Est. completion date December 30, 2025

Study information

Verified date May 2024
Source Tarapeutics Science Inc.
Contact Yang Shu, MD, BS.
Phone +8613918983465
Email shuyang@tarapeutics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.


Description:

This is a open-label, dose escalation and expansion, accelerated titration combined 3+3 design, phase 1 study, to evaluate the safety and tolerability, and to determine the Recommeded Phase II Dose (RP2D) of TR115 when administered bid in patients with non-hodgkin's lymphoma or advanced solid tumors. During the dose escalation phase, Up to 6 cohorts of 1-6 0r 3-6 patients each will be treated in the study. Patients will receive study treatment until criteria for study termination are met. A safety Follow-up Visit will conducted 30 days (±7 days) after the last dose of treatment. Patients who discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, lost to follow-up, death, or until the sponsor stops the study, whichever comes first. After finishing the dose escalation phase, a dose extension phase will be initiated with additional patients included in order to further evaluate the tolerability, pharmacokinetics, and efficacy at the recommended dose that have been evaluated in the dose escalation phase. Adverse events will be assessed using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Tumor response will be assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) scan using Lugano 2014/RECIST 1.1 criteria, assessed by the investigator.


Recruitment information / eligibility

Status Recruiting
Enrollment 26
Est. completion date December 30, 2025
Est. primary completion date July 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol. - males and/or females at least 18 years old when signing the informed consent form. - tumor type criteria: 1. relapsed/refractory histologically or cytologically documented non-hodgkin's lymphoma must have received at least 1 prior systemic therapies, including but not limited as below: Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Peripheral T-cell lymphoma-Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL), Anaplastic Large Cell Lymphoma (ALCL). 2. histologically or cytologically confirmed patients with advanced malignant solid tumors, eligible patients must have failed standard treatment, no standard treatment, or not suitable for standard treatment at this stage as determined by the investigator. - eastern cooperative oncology group performance status (ECOG) =2 at screening. - life expectancy of at least 3 months. - acceptable organ function: absolute neutrophil count (ANC)=1.0×109/L (note: growth factor supports within 14 days of the first dose); platelet count (PLT)=90×109/L (note: PLT=70 × 109/L for patients with Non-Hodgkin Lymphoma (NHL) and =50 × 109/L allowed in patients with bone marrow infiltration. no blood product transfusion is allowed within 14 days of the first dose); hemoglobin (Hb) =90g/L (note: Hb =80g/L for patients with NHL and =70g/L in patients with bone marrow infiltration. no blood product transfusion is allowed within 14 days of the first dose); International Normalized Ratio (INR) or Prothrombin Time (PT)=1.5×Upper limit of normal value (ULN), Activated Partial Thromboplastin Time (APTT)=1.5×ULN ;Total bilirubin (TBIL)=1.5×ULN, Aspartate Amino Tranferase (AST) and Alanine Transaminase (ALT)=2.5×ULN (note: = 5 × ULN if there is liver involvement); Creatinine (Cr) =1.5×ULN or Creatinine Clearance (CCr) =50 ml/min (calculated by Cockcroft-Gault formula). - fertile male and female must agree to use medically approved contraceptives during the study and within 6 months after the last dose of the study. Key Exclusion Criteria: - known or suspected allergies to any of the investigational drug compositon. - medical history and surgical history excluded according to the protocol. - any previous medical treatment history exclude from the protocol. - abnormal laboratory results exclude from the protocol. - pregnant and lactating women (currently breast-feeding or less than six months after delivery although not breast-feeding). - subjects may not be able to complete the study due to poor compliance or other reasons, or unsuitable for the study by the investigator's judgment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TR115
TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).

Locations

Country Name City State
China The first affiliated hospital, Zhejiang university school of medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Tarapeutics Science Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other ORR efficacy-overall response rate Throughout the study for approximately 2 years
Other PFS efficacy-progression free survival Throughout the study for approximately 2 years
Other DOR efficacy-duration of response Throughout the study for approximately 2 years
Other CBR efficacy--clinical benefit rate Throughout the study for approximately 2 years
Primary Adverse events and serious adverse events frequency, duration and severity of adverse events and serious adverse events evaluated by NCI CTCAE 5.0 from the first dose to within 30 days after the last dose
Primary dose limited toxicities incidence of dose limited toxicities within 31 days after the first dose
Primary maximum tolerated dose evaluated by safety review committee Throughout the study for approximately 2 years
Primary recommedded phase 2 dose evaluated by safety review committee Throughout the study for approximately 2 years
Secondary AUClast characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
Secondary AUCinf characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
Secondary Cmax characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
Secondary Tmax characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
Secondary CL/F characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
Secondary Vz/F characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
Secondary Terminal half-life (T1/2) characterize the pharmacokinetic profile of TR115 within 31 days after the first dose
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1